Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3

Transplantation

Volumn 93, Issue 5, 2012, Pages 477-484

  Dang, Zexu ^a   MacKinnon, Alison ^a   Marson, Lorna P ^a   Sethi, Tariq ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Denmark Hill Campus ^*  (United Kingdom)

Author keywords

Fibrosis; Galectin 3; Kidney transplant; Macrophage

Indexed keywords

CELL MARKER; COLLAGEN TYPE 1; GALECTIN 3; INTERLEUKIN 4; UNCLASSIFIED DRUG; YM1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; MACROPHAGE ACTIVATION; MOLECULAR PATHOLOGY; MOUSE; MYOFIBROBLAST; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE PRESERVATION; UPREGULATION; WILD TYPE;

ANIMALS; ATROPHY; CD4-POSITIVE T-LYMPHOCYTES; FIBROSIS; GALECTIN 3; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-4; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TIME FACTORS; TRANSPLANTATION, ISOGENEIC;

EID: 84857641155     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318242f40a     Document Type: Article

References (29)

1. Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. Kidney Int 2002;62:1848.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289.
3. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999;187:481.
4. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288.
5. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060.
6. Farnworth SL, Henderson NC, Mackinnon AC, et al. Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. Am J Pathol 2008;172:395.
7. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008;180:2650.
8. Nair MG, Cochrane DW, Allen JE. Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol Lett 2003;85:173.
9. Raes G, Brys L, Dahal BK, et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukocyte Biol 2005;77:321.
10. Ozdemir BH, Demirhan B, Gungen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. Nephron 2002;90:442.
11. Beckmann N, Cannet C, Zurbruegg S, et al. Macrophage infiltration detected at MR imaging in rat kidney allografts: Early marker of chronic rejection? Radiology 2006;240:717.
12. Qi F, Adair A, Ferenbach D, et al. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 2008;86:1267.
13. Adair A, Mitchell DR, Kipari T, et al. Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Transplantation 2007;83:1542.
14. Duffield JS. The inflammatory macrophage: A story of Jekyll and Hyde. Clin Sci (Lond) 2003;104:27.
15. Ferenbach D, Kluth DC, Hughes J. Inflammatory cells in renal injury and repair. Semin Nephrol 2007;27:250.
16. Goerdt S, Orfanos CE. Other functions, other genes: Alternative activation of antigen-presenting cells. Immunity 1999;10:137.
17. Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: Amarker of alternative immunologic macrophage activation. J Exp Med 1992;176:287.
18. Raes G, Noel W, Beschin A, et al. FIZZ1 and Ym as tools to discriminate between differentially activated macrophages, Develop Immunol 2002;9:151.
19. Lin SL, Castano AP, Nowlin BT, et al. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009;183:6733.
20. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev 2009;230:114.
21. Okamura DM, Pasichnyk K, Lopez-Guisa JM, et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 2011;300:F245.
22. Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57.
23. Liu HY, Huang ZL, Yang GH, et al. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol 2008;14:7386.
24. Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994;11:527.
25. Kolatsi-Joannou M, Price KL, Winyard PJ, et al. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011;6:e18683.
26. Brown K, Sacks SH, Wong W. Tertiary lymphoid organs in renal allografts can be associated with donor-specific tolerance rather than rejection. Eur J Immunol 2010;41:89.
27. Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000;156:1073.
28. Mannon RB, Kopp JB, Ruiz P, et al. Chronic rejection of mouse kidney allografts. Kidney Int 1999;55:1935.
29. Win TS, Rehakova S, Negus MC, et al. Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circ Heart Fail 2009;2:361.